BioLife Solutions sells cold chain logistics subsidiary for $25.5 million

BOTHELL, Wash. - BioLife Solutions, Inc. (NASDAQ:BLFS), a developer and supplier of cell processing tools for the cell and gene therapy market with a market capitalization of $1.27 billion, announced Tuesday the sale of its cold chain logistics subsidiary SAVSU Cleo Technologies to Peli BioThermal for $25.5 million in cash, subject to certain adjustments. According to InvestingPro data, the company has demonstrated impressive revenue growth of 68% in the last twelve months.

The transaction divests BioLife of SAVSU, formerly known as SAVSU Technologies, Inc., which specializes in cold chain logistics technology for biological materials.

"This divestiture streamlines our product portfolio as well as our operations while focusing resources on creating shareholder value through high-margin recurring revenue," said Roderick de Greef, Chairman and CEO of BioLife Solutions. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 4.43, indicating robust financial health for future operations.

BioLife Solutions develops and supplies tools and services for the cell and gene therapy market, with products designed to maintain the health and function of biological materials during collection, development, manufacturing and distribution processes.

Peli BioThermal, the acquirer, is a global provider of temperature-controlled logistics solutions. The company will take ownership of SAVSU’s evo technology platform.

The announcement was made in a press release statement from BioLife Solutions. The transaction represents a strategic move by the company to refocus on its core business operations in the cell processing tools sector. For deeper insights into BioLife Solutions’ financial health and growth prospects, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.

In other recent news, BioLife Solutions reported its second-quarter 2025 financial results, revealing a total revenue of $25.4 million, which marks a 29% increase compared to the previous year. This figure surpassed the projection of $24.2 million by H.C. Wainwright. Despite the revenue growth, the company experienced a net loss of $15.8 million, or $0.33 per share, which was larger than anticipated due to a $15.5 million in-process R&D expense related to the PanTHERA transaction. In light of these results, H.C. Wainwright adjusted its price target for BioLife Solutions from $30 to $32, maintaining a Buy rating. Additionally, KeyBanc reiterated its Overweight rating with a price target of $33.00, pointing to multiple growth avenues for the company. In corporate governance matters, BioLife Solutions held its 2025 annual meeting, where shareholders re-elected all seven director nominees and approved executive compensation. They also ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These developments reflect ongoing investor interest and strategic focus within the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.